HK1139073A1 - - Google Patents

Info

Publication number
HK1139073A1
HK1139073A1 HK10105737.5A HK10105737A HK1139073A1 HK 1139073 A1 HK1139073 A1 HK 1139073A1 HK 10105737 A HK10105737 A HK 10105737A HK 1139073 A1 HK1139073 A1 HK 1139073A1
Authority
HK
Hong Kong
Prior art keywords
salt forms
phenyl
new salt
hsp90
polymorphs
Prior art date
Application number
HK10105737.5A
Other languages
English (en)
Inventor
Martin James Drysdale
Brian William Dymock
Christoph Krell
Michael Mutz
Holger Petersen
Weijia Zheng
Original Assignee
Novartis Ag
Vernalis R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38134307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1139073(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Vernalis R&D Ltd filed Critical Novartis Ag
Publication of HK1139073A1 publication Critical patent/HK1139073A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
HK10105737.5A 2007-03-01 2010-06-09 HK1139073A1 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07103346 2007-03-01
PCT/EP2008/052443 WO2008104595A1 (en) 2007-03-01 2008-02-28 Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms

Publications (1)

Publication Number Publication Date
HK1139073A1 true HK1139073A1 (xx) 2010-09-10

Family

ID=38134307

Family Applications (1)

Application Number Title Priority Date Filing Date
HK10105737.5A HK1139073A1 (xx) 2007-03-01 2010-06-09

Country Status (41)

Country Link
US (3) US8163747B2 (xx)
EP (2) EP2131845B1 (xx)
JP (1) JP2010520176A (xx)
KR (1) KR20090122218A (xx)
CN (2) CN101636162A (xx)
AR (1) AR065519A1 (xx)
AT (1) ATE552836T1 (xx)
AU (1) AU2008220800B2 (xx)
BR (1) BRPI0807992A2 (xx)
CA (1) CA2678043A1 (xx)
CL (1) CL2008000618A1 (xx)
CO (1) CO6210828A2 (xx)
CR (1) CR10989A (xx)
CY (1) CY1113805T1 (xx)
DK (1) DK2131845T3 (xx)
DO (1) DOP2009000209A (xx)
EA (1) EA017075B1 (xx)
EC (1) ECSP099602A (xx)
ES (1) ES2384906T3 (xx)
GE (1) GEP20115309B (xx)
GT (1) GT200900236A (xx)
HK (1) HK1139073A1 (xx)
HR (1) HRP20120535T1 (xx)
IL (1) IL200401A0 (xx)
MA (1) MA31204B1 (xx)
MX (1) MX2009009233A (xx)
NI (1) NI200900161A (xx)
NZ (1) NZ578854A (xx)
PA (1) PA8771101A1 (xx)
PE (1) PE20090166A1 (xx)
PL (1) PL2131845T3 (xx)
PT (1) PT2131845E (xx)
RS (1) RS52351B (xx)
SI (1) SI2131845T1 (xx)
SM (1) SMAP200900080A (xx)
TN (1) TN2009000357A1 (xx)
TW (1) TW200844102A (xx)
UA (1) UA101950C2 (xx)
UY (1) UY30943A1 (xx)
WO (1) WO2008104595A1 (xx)
ZA (1) ZA200905417B (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200922595A (en) * 2007-10-12 2009-06-01 Novartis Ag Organic compounds
TWI450898B (zh) * 2008-07-04 2014-09-01 Sigma Tau Res Switzerland Sa 具有抗腫瘤活性之芳基異唑化合物
JP5063815B2 (ja) * 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
JP5845193B2 (ja) 2010-01-21 2016-01-20 アプレア エイビー 過増殖性疾患、自己免疫疾患、および心疾患の治療のための3−キヌクリジノンを含有する水溶液
KR101392086B1 (ko) * 2010-02-17 2014-05-07 일동제약주식회사 신규 5각 헤테로 고리 유도체 및 그 제조방법
KR20120031854A (ko) 2010-09-27 2012-04-04 한국전자통신연구원 시간 및 주파수 특징을 이용하는 음악 음원 분리 장치 및 방법
WO2013015661A2 (en) * 2011-07-28 2013-01-31 Ildong Pharm Co.,Ltd. Novel prodrugs of 5-(2,4-dihydroxy-5-isopropylphenyl)-n-ethyl-4-(5-methyl1-1,2,4-oxadiazol-3-yl)isoxazole-3-carboxamide
FR3039401B1 (fr) * 2015-07-31 2018-07-13 Les Laboratoires Servier Nouvelle association entre le 3-[(3-{[4-(4-morpholinylmethyl)-1h-pyrrol-2-yl]methylene}-2-oxo-2,3-dihydro-1h-indol-5-yl)methyl]-1,3-thiazolidine-2,4-dione et un inhibiteur de la tyr kinase du egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101166749B1 (ko) * 2003-02-11 2012-07-27 베르날리스(캠브리지)리미티드 열쇼크 단백질 저해제로서의 이소옥사졸 화합물
US20060070405A1 (en) * 2004-10-06 2006-04-06 Anheuser-Busch, Inc. Method for the production of amber glass with reduced sulfur-containing emissions
AU2008216327A1 (en) 2007-02-15 2008-08-21 Novartis Ag Combination of LBH589 with other therapeutic agents for treating cancer
WO2010069458A1 (de) 2008-12-17 2010-06-24 Merck Patent Gmbh Hexahalochromat(lll)-komplexe

Also Published As

Publication number Publication date
ECSP099602A (es) 2009-12-28
CO6210828A2 (es) 2010-10-20
EP2545921A2 (en) 2013-01-16
PA8771101A1 (es) 2009-02-09
DK2131845T3 (da) 2012-07-16
EP2545921A3 (en) 2013-04-10
PT2131845E (pt) 2012-07-10
CN102302500A (zh) 2012-01-04
US20120172592A1 (en) 2012-07-05
EP2131845A1 (en) 2009-12-16
EA017075B1 (ru) 2012-09-28
AU2008220800A1 (en) 2008-09-04
SMAP200900080A (it) 2010-01-19
HRP20120535T1 (hr) 2012-07-31
IL200401A0 (en) 2010-04-29
CY1113805T1 (el) 2016-07-27
WO2008104595A1 (en) 2008-09-04
GT200900236A (es) 2011-09-14
KR20090122218A (ko) 2009-11-26
EP2131845B1 (en) 2012-04-11
TW200844102A (en) 2008-11-16
US20130296556A1 (en) 2013-11-07
AU2008220800B2 (en) 2012-02-16
UY30943A1 (es) 2008-10-31
CL2008000618A1 (es) 2008-09-12
US8487095B2 (en) 2013-07-16
MA31204B1 (fr) 2010-02-01
DOP2009000209A (es) 2009-09-15
ATE552836T1 (de) 2012-04-15
TN2009000357A1 (en) 2010-12-31
BRPI0807992A2 (pt) 2014-06-17
PL2131845T3 (pl) 2012-09-28
PE20090166A1 (es) 2009-03-14
US20100093732A1 (en) 2010-04-15
EA200901141A1 (ru) 2010-04-30
MX2009009233A (es) 2010-06-02
UA101950C2 (ru) 2013-05-27
ES2384906T3 (es) 2012-07-13
JP2010520176A (ja) 2010-06-10
CA2678043A1 (en) 2008-09-04
CR10989A (es) 2010-03-01
ZA200905417B (en) 2010-05-26
GEP20115309B (en) 2011-10-25
US8163747B2 (en) 2012-04-24
NI200900161A (es) 2010-07-27
CN101636162A (zh) 2010-01-27
RS52351B (en) 2012-12-31
NZ578854A (en) 2012-03-30
AR065519A1 (es) 2009-06-10
SI2131845T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
HK1139073A1 (xx)
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
EA201101308A1 (ru) Применение ралфинамида для лечения биполярного расстройства
NO20085066L (no) 4,5-difenyl-pyrimidinyl-aminosubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
AU2018236805B2 (en) Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives
IL183415A0 (en) Tartrate salt of isofagomine and methods of use
MY149731A (en) Compounds
UA88481C2 (ru) Донепезила фумарат, пригодный для получения фармацевтических композиций
NZ592543A (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
EA201100063A1 (ru) СПОСОБ ПОЛУЧЕНИЯ ПИРИДО-ПИРИМИДИНОВЫХ ИНГИБИТОРОВ mTOR КИНАЗЫ, ИХ СОЛЕВЫХ ФОРМ И ИХ ЛЕКАРСТВЕННЫХ ПРЕПАРАТОВ
NZ582284A (en) Carbamoyl-cyclohexanes for treating acute mania
MX2010007426A (es) Composiciones farmaceuticas para tratar trastorno del higado graso.
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
NZ593282A (en) Ethanamine compounds and their use for treating depression
CU20090151A7 (es) Sales de adición de ácido, hidratos y polimorfos de la etil-amida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, y formulaciones que comprenden estas formas
MXPA05013717A (es) Derivados de acido 2-etoxi-2-fenilpropionico para el tratamiento de trastornos de lipido.
TW200635575A (en) Use of substituted cyclopropane acid derivatives for producing medicaments for treating the metabolic syndrome
EA201100826A1 (ru) Холиновые соли янтарной кислоты для лечения депрессий, страхов, шизофрении, нарушений сна и эпилепсии
TH123699A (th) สารประกอบ 4-[2-(2-ฟลูออโรฟีนอกซิเมธิล)เฟนิล]พิเพอริดีน

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160228